Poseida Therapeutics News

Poseida Therapeutics Announces Virtual 2024 Annual Meeting of Stockholders

SAN DIEGO, June 3, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments

PR NewswireJun 4 04:05

H.C. Wainwright Maintains Poseida Therapeutics(PSTX.US) With Buy Rating, Maintains Target Price $20

H.C. Wainwright analyst Arthur He CFA maintains $Poseida Therapeutics(PSTX.US)$ with a buy rating, and maintains the target price at $20.According to TipRanks data, the analyst has a success rate of 5

Futu NewsMay 23 20:33

Analysts Offer Insights on Healthcare Companies: Poseida Therapeutics (PSTX), Greenwich LifeSciences (GLSI) and ACELYRIN, INC. (SLRN)

TipRanksMay 22 18:20

HC Wainwright & Co. : The Poseida Therapeutics (PSTX.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $20.00.

HC Wainwright & Co. : The Poseida Therapeutics (PSTX.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $20.00.

Zhitong FinanceMay 22 18:10

Poseida Therapeutics Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results.

Poseida Therapeutics Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results.

BenzingaMay 15 23:51

Piper Sandler Reaffirms Their Buy Rating on Poseida Therapeutics (PSTX)

TipRanksMay 15 20:18

Poseida Therapeutics: A Strong Buy on Robust Pipeline, Strategic Partnerships, and Leadership Enhancements

TipRanksMay 15 15:55

Poseida Therapeutics Q1 Net Loss Narrows, Revenue Rises

Poseida Therapeutics (PSTX) reported a Q1 loss late Tuesday of $0.25 per diluted share, narrowing from a loss of $0.45 a year earlier. Four of five analysts polled by Capital IQ expected a loss of $0.

MT NewswiresMay 15 05:08

Poseida Therapeutics Q1 2024 Adj EPS $(0.25) Beats $(0.42) Estimate, Sales $28.14M Beat $11.67M Estimate

Poseida Therapeutics (NASDAQ:PSTX) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.42) by 40.48 percent. The company reported quarterly sales of $28.14

BenzingaMay 15 04:26

Poseida Therapeutics | 10-Q: Quarterly report

SEC announcementMay 15 04:20 · Announcements

Earnings Flash (PSTX) POSEIDA THERAPEUTICS Reports Q1 Revenue $28.1M

04:12 PM EDT, 05/14/2024 (MT Newswires) -- Earnings Flash (PSTX) POSEIDA THERAPEUTICS Reports Q1 Revenue $28.1M

MT NewswiresMay 15 04:12

Press Release: Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2024

Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2024 PR Newswire SAN DIEGO, May 14, 2024 Expanded strategic relationship with Astellas with new research collabo

Dow JonesMay 15 04:05

Poseida Therapeutics 1Q Loss/Shr 25c >PSTX

Poseida Therapeutics 1Q Loss/Shr 25c >PSTX

Dow JonesMay 15 04:05

Poseida Highlights Strong Progress on Its Genetic Medicine Programs at the American Society for Gene and Cell Therapy 27th Annual Meeting

PRNewswireMay 9 21:00

Broker Revenue Forecasts For Poseida Therapeutics, Inc. (NASDAQ:PSTX) Are Surging Higher

Yahoo FinanceMay 3 18:46

Strong Buy Rating for Poseida Therapeutics Amidst Strategic Partnerships and Robust CAR-T Manufacturing Capabilities

TipRanksMay 2 18:30

Strategic Advancements and Favorable Deal Terms Reinforce Buy Rating for Poseida Therapeutics

TipRanksMay 2 18:07

Poseida Therapeutics to Receive Up to $600 Million in Cancer Gene Therapy Research, Development Deal With Xyphos

Poseida Therapeutics (PSTX) and Astellas Pharma subsidiary Xyphos Biosciences have entered into a research partnership and license agreement to develop new cancer cell therapy platforms using the Xyph

MT NewswiresMay 2 18:04

Biotech Soars on Research Collaboration And License Agreement Release

YolowireMay 2 02:39

Poseida Gains on Cell Therapy Pact With Astellas

Seeking AlphaMay 2 01:54